ProfoundBio

ProfoundBio is a clinical-stage biotechnology company founded in 2018 that develops next-generation antibody-drug conjugate (ADC) therapies for cancer . The company built a proprietary technology platform around ADCs—antibody-based treatments that link highly potent cytotoxic drugs to tumor-targeting antibodies to strike specific cancers while sparing healthy tissue . Its disclosed pipeline as of early 2024 included four main candidates: Rina-S (PRO1184), a folate receptor α-targeting ADC in Phase 2 for ovarian and endometrial cancers that had received FDA Fast Track designation ; PRO1160, a CD70-targeting ADC in Phase 1 ; PRO1107, a PTK7-targeting ADC also in Phase 1 ; and PRO1286, a bispecific ADC expected to enter clinical development in 2024 .

The company raised over $112 million in total funding across multiple rounds, with investors including Lilly Asia Ventures, LYFE Capital, Sequoia China, and Gaorong Ventures, which participated from the Pre-A round onward . Co-founder, CEO, and Chairman Baiteng Zhao led the team . In April 2024, Danish biotech Genmab acquired ProfoundBio for $1.8 billion in an all-cash deal, gaining global rights to its ADC pipeline and technology platform .